PMC Links for Books (Select 4434836) - PMC

Select item 73470851.

Factors influencing pharmacokinetics of warfarin in African–Americans: implications for pharmacogenetic dosing algorithms

Rui Nagai, Minami Ohara, Larisa H Cavallari, Katarzyna Drozda, Shitalben R Patel, Edith A Nutescu, Minoli A Perera, Wenndy Hernandez, Naoko Kaneko, Manabu Hibiya, Harumi Takahashi

Pharmacogenomics. Author manuscript; available in PMC 2020 Jul 9.

Published in final edited form as: Pharmacogenomics. 2015; 16(3): 217–225. doi: 10.2217/pgs.14.160

PMCID:: PMC7347085

Article PDF–710K

Select item 56989052.

Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew Hill, John Wagstaff, Matteo S. Carlino, John B. Haanen, Michele Maio, Ivan Marquez-Rodas, Grant A. McArthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth Grossmann, Mario Sznol, Brigitte Dreno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine Horak, F. Stephen Hodi, Jedd D. Wolchok

N Engl J Med. Author manuscript; available in PMC 2017 Nov 22.

Published in final edited form as: N Engl J Med. 2015 Jul 2; 373(1): 23–34. Published online 2015 May 31. doi: 10.1056/NEJMoa1504030

PMCID:: PMC5698905

Article PDF–368K

Select item 48304863.

Treatment of NRAS-Mutant Melanoma

Douglas B. Johnson, Igor Puzanov

Curr Treat Options Oncol. Author manuscript; available in PMC 2016 Apr 13.

Published in final edited form as: Curr Treat Options Oncol. 2015 Apr; 16(4): 15. doi: 10.1007/s11864-015-0330-z

PMCID:: PMC4830486

Article PDF–164K

Select item 48269714.

Off-label use of targeted therapies in oncology

Dominique Levêque

World J Clin Oncol. 2016 Apr 10; 7(2): 253–257. Published online 2016 Apr 10. doi: 10.5306/wjco.v7.i2.253

PMCID:: PMC4826971

Article PDF–699K

Select item 46992645.

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

Zeynep Eroglu, Antoni Ribas

Ther Adv Med Oncol. 2016 Jan; 8(1): 48–56. doi: 10.1177/1758834015616934

PMCID:: PMC4699264

Article PDF–394K

Select item 44534406.

Beyond BRAF: where next for melanoma therapy?

I V Fedorenko, G T Gibney, V K Sondak, K S M Smalley

Br J Cancer. 2015 Jan 20; 112(2): 217–226. Published online 2014 Sep 2. doi: 10.1038/bjc.2014.476

PMCID:: PMC4453440

Article PDF–282K

Select item 43826327.

Safety and efficacy of vemurafenib in BRAF^V600E and BRAF^V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Prof. Grant A McArthur, Prof. Paul B Chapman, Caroline Robert, James Larkin, John B Haanen, Prof. Reinhard Dummer, Prof. Antoni Ribas, Prof. David Hogg, Omid Hamid, Paolo A Ascierto, Prof. Claus Garbe, Alessandro Testori, Michele Maio, Paul Lorigan, Prof. Celeste Lebbé, Thomas Jouary, Prof. Dirk Schadendorf, Stephen J O’Day, Prof. John M. Kirkwood, Prof. Alexander M Eggermont, Prof. Brigitte Dréno, Prof. Jeffrey A Sosman, Keith T Flaherty, Ming Yin, Ivor Caro, Suzanne Cheng, Kerstin Trunzer, Prof. Axel Hauschild

Lancet Oncol. Author manuscript; available in PMC 2015 Apr 2.

Published in final edited form as: Lancet Oncol. 2014 Mar; 15(3): 323–332. Published online 2014 Feb 7. doi: 10.1016/S1470-2045(14)70012-9

PMCID:: PMC4382632

Article PDF–912K

Select item 43517978.

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

Douglas B. Johnson, Christine M. Lovly, Marisa Flavin, Katherine S. Panageas, Gregory D. Ayers, Zhiguo Zhao, Wade T. Iams, Marta Colgan, Sarah DeNoble, Charles R. Terry, Elizabeth G. Berry, A. John Iafrate, Ryan J. Sullivan, Richard D. Carvajal, Jeffrey A. Sosman

Cancer Immunol Res. Author manuscript; available in PMC 2016 Mar 1.

Published in final edited form as: Cancer Immunol Res. 2015 Mar; 3(3): 288–295. doi: 10.1158/2326-6066.CIR-14-0207

PMCID:: PMC4351797

Article PDF–915K

Select item 42793679.

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

Francesco Spagnolo, Paola Ghiorzo, Paola Queirolo

Oncotarget. 2014 Nov; 5(21): 10206–10221. Published online 2014 Oct 18. doi: 10.18632/oncotarget.2602

PMCID:: PMC4279367

Article PDF–1.8M

Select item 354929610.

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert, John B. Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Celeste Lebbe, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven J. O’Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur, BRIM-3 Study Group

N Engl J Med. Author manuscript; available in PMC 2013 Jan 19.

Published in final edited form as: N Engl J Med. 2011 Jun 30; 364(26): 2507–2516. Published online 2011 Jun 5. doi: 10.1056/NEJMoa1103782

PMCID:: PMC3549296

Article PDF–1.0M

Select item 342146311.

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma

Rosalie Fisher, James Larkin

Cancer Manag Res. 2012; 4: 243–252. Published online 2012 Aug 8. doi: 10.2147/CMAR.S25284

PMCID:: PMC3421463

Article PDF–206K

Select item 330623612.

BRAF mutation predicts sensitivity to MEK inhibition

David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose M. Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith Sebolt-Leopold, William R. Sellers, Neal Rosen

Nature. Author manuscript; available in PMC 2012 Mar 16.

Published in final edited form as: Nature. 2006 Jan 19; 439(7074): 358–362. Published online 2005 Nov 6. doi: 10.1038/nature04304

PMCID:: PMC3306236

Article PDF–1.7M

Select item 326669513.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay, Maayan Salton, Kimberly B. Dahlman, Madhavi Tadi, Jennifer A. Wargo, Keith T. Flaherty, Mark C. Kelley, Tom Misteli, Paul B. Chapman, Jeffrey A. Sosman, Thomas G. Graeber, Antoni Ribas, Roger S. Lo, Neal Rosen, David B. Solit

Nature. Author manuscript; available in PMC 2012 Jun 15.

Published in final edited form as: Nature. 2011 Dec 15; 480(7377): 387–390. Published online 2011 Nov 23. doi: 10.1038/nature10662

PMCID:: PMC3266695

Article PDF–580K

Select item 314336014.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant McArthur, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo

Nature. Author manuscript; available in PMC 2011 Dec 16.

Published in final edited form as: Nature. 2010 Dec 16; 468(7326): 973–977. Published online 2010 Nov 24. doi: 10.1038/nature09626

PMCID:: PMC3143360

Article PDF–1.4M

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from Books

Items: 14

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity